E2F4 Promotes the Proliferation of Hepatocellular Carcinoma Cells through Upregulation of CDCA3
- PMID: 34335934
- PMCID: PMC8317516
- DOI: 10.7150/jca.53708
E2F4 Promotes the Proliferation of Hepatocellular Carcinoma Cells through Upregulation of CDCA3
Abstract
Liver cancer, the second most commonly diagnosed cancer, is associated with high mortality rates. E2F4 is a member of the E2F transcription factor family. There are limited studies on the role of E2F4 in hepatocellular carcinoma (HCC). In this study, the expression of E2F4 in HCC tissue samples and cell lines was analyzed using quantitative real-time polymerase chain reaction. E2F4 expression positively correlated with tumor size in patients with HCC. Additionally, E2F4 expression was greater in HCC cells than in normal LO2 cells. Furthermore, overexpression of E2F4 significantly enhanced the proliferation, migration, and invasion of HCC cells. The results of a luciferase assay revealed that E2F4 upregulated the expression of CDCA3 by binding to its promoter region (1863'-ACGCGCGAGAATG-1875') and consequently promoted proliferation and cell cycle progression of HCC cells. Taken together, these results demonstrated that E2F4 might play a vital role in HCC progression and could serve as a potential biomarker for the diagnosis and as a therapeutic target of HCC.
Keywords: CDCA3; E2F4; hepatocellular carcinoma; promoter.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures




Similar articles
-
Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9.Int J Oncol. 2024 Oct;65(4):98. doi: 10.3892/ijo.2024.5686. Epub 2024 Sep 6. Int J Oncol. 2024. PMID: 39239750 Free PMC article.
-
Transcription factor E2F4 is an indicator of poor prognosis and is related to immune infiltration in hepatocellular carcinoma.J Cancer. 2021 Jan 21;12(6):1792-1803. doi: 10.7150/jca.51616. eCollection 2021. J Cancer. 2021. PMID: 33613768 Free PMC article.
-
DNA hypomethylation promotes invasion and metastasis of gastric cancer cells by regulating the binding of SP1 to the CDCA3 promoter.J Cell Biochem. 2020 Jan;121(1):142-151. doi: 10.1002/jcb.28993. Epub 2019 Jun 18. J Cell Biochem. 2020. PMID: 31211445
-
HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.Cell Physiol Biochem. 2018;50(6):2124-2138. doi: 10.1159/000495056. Epub 2018 Nov 9. Cell Physiol Biochem. 2018. PMID: 30415263
-
Knockdown of E2F4 suppresses the growth of ovarian cancer cells through the cell cycle pathway.Int J Clin Exp Pathol. 2021 Aug 15;14(8):866-874. eCollection 2021. Int J Clin Exp Pathol. 2021. PMID: 34527129 Free PMC article.
Cited by
-
Prognostic value of CDCA3 in kidney renal papillary cell carcinoma.Aging (Albany NY). 2021 Dec 14;13(23):25466-25483. doi: 10.18632/aging.203767. Epub 2021 Dec 14. Aging (Albany NY). 2021. PMID: 34905505 Free PMC article.
-
Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9.Int J Oncol. 2024 Oct;65(4):98. doi: 10.3892/ijo.2024.5686. Epub 2024 Sep 6. Int J Oncol. 2024. PMID: 39239750 Free PMC article.
-
Roles of the CDCA gene family in breast carcinoma.Sci Prog. 2025 Jan-Mar;108(1):368504241312305. doi: 10.1177/00368504241312305. Sci Prog. 2025. PMID: 39814554 Free PMC article.
-
Exploring Key Biomarkers and Common Pathogenesis of Seven Digestive System Cancers and Their Correlation with COVID-19.Curr Issues Mol Biol. 2023 Jun 30;45(7):5515-5533. doi: 10.3390/cimb45070349. Curr Issues Mol Biol. 2023. PMID: 37504265 Free PMC article.
-
NUCB2 promotes hepatocellular carcinoma cell growth and metastasis by activating the E2F4/PTGR1 axis.Int J Biol Sci. 2024 Sep 3;20(12):4767-4780. doi: 10.7150/ijbs.97861. eCollection 2024. Int J Biol Sci. 2024. PMID: 39309426 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. - PubMed
-
- Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–750. - PubMed
-
- Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene. 2005;24:2810–2826. - PubMed
LinkOut - more resources
Full Text Sources